prediction, absorption, distribution, multiple drug target prediction and network analysis to analyze drugs, drug targets, pathways and drug effects". This approach, which can be used in the discovery of single bioactive ingredients, can help to identify he mechanisms of drug action 0, I Hepatitis B(HB)is an infectious disease caused by the hepatitis B virus(HBv) There are approximately 350 million individuals worldwide that carry the HBv, and China has a high incidence, with approximately 120 million carriers. Chronic HBV infection can lead to hepatitis, cirrhosis and hepatocellular carcinoma(HCC), and effective treatments are lacking. Because of the high morbidity and mortality, hepatitis b vaccination is essential for reducing the carrier rate and preventing viral infection The currently used genetically engineered hepatitis b vaccine with aluminum hydroxide as the conventional adjuvant has low efficacy, a long waiting period to immune response and large individual differences in immune effects. Approximately 5-10% of individuals with a normal immune system cannot achieve effective immunity against hepatitis b virus infection Therefore, developing a quick and effective adjuvant to enhance hepatitis b vaccine immunogenicity is of great practical Ophiocordyceps sinensis(syn. Cordyceps sinensis), placed systematically as Ophiocordycipitaceae, Hypocreales, Hypocreomycetidae, Sordariomycetes, Ascomycota, is a TCM agent that has been widely used as a folk tonic for nearly one thousand years. It has an overwhelming list of pharmacological properties 8-.As one of the traditional and medical fungi, O. sinensis is currently available in China3 prediction, absorption, distribution, multiple drug target prediction and network analysis to analyze drugs, drug targets, pathways and drug effects8,9. This approach, which can be used in the discovery of single bioactive ingredients, can help to identify the mechanisms of drug action10,11. Hepatitis B (HB) is an infectious disease caused by the hepatitis B virus (HBV). There are approximately 350 million individuals worldwide that carry the HBV, and China has a high incidence, with approximately 120 million carriers12. Chronic HBV infection can lead to hepatitis, cirrhosis and hepatocellular carcinoma (HCC), and effective treatments are lacking. Because of the high morbidity and mortality, hepatitis b vaccination is essential for reducing the carrier rate and preventing viral infection13. The currently used genetically engineered hepatitis b vaccine with aluminum hydroxide as the conventional adjuvant has low efficacy, a long waiting period to immune response and large individual differences in immune effects. Approximately 5-10% of individuals with a normal immune system cannot achieve effective immunity against hepatitis b virus infection14-16. Therefore, developing a quick and effective adjuvant to enhance hepatitis b vaccine immunogenicity is of great practical value. Ophiocordyceps sinensis (syn. Cordyceps sinensis), placed systematically as Ophiocordycipitaceae, Hypocreales, Hypocreomycetidae, Sordariomycetes, Ascomycota, is a TCM agent that has been widely used as a folk tonic for nearly one thousand years17. It has an overwhelming list of pharmacological properties18-21. As one of the traditional and medical fungi, O. sinensis is currently available in China